Archives: BioMedWire

November 16, 2021 15:06:40

InMed Pharmaceuticals (NASDAQ: INM) and its subsidiary BayMedica are innovators in the field of rare cannabinoids, making them available for consumer access. InMed specializes in developing a proprietary biosynthesis system to manufacture pharmaceutical-grade cannabinoids that are otherwise too rare to be acquired in abundance. Through BayMedica, its recent acquisition, InMed also has capabilities in both yeast biosynthesis and chemical synthesis, catering to the large and growing health and wellness consumer markets. “The cannabis plant is made up of over 100 unique cannabinoids, many of which are only found in trace amounts,” reads a recent article. “With so many of these cannabinoids exhibiting the potential to fulfill several unmet medical needs industry-wide, InMed is working on the answer to mass production of rare and otherwise depleted cannabinoid opportunities. Unlike tetrahydrocannabinol (‘THC’) and cannabidiol (‘CBD’), which are found in excess within the cannabis plant, the goal for InMed and BayMedica is to use various manufacturing approaches to produce the amounts of rare cannabinoids necessary to fulfill the outstanding medical need in the industry.” To view the full article, visit https://ibn.fm/EGVxs About InMed Pharmaceuticals Inc. InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed Pharmaceuticals is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Roundtable

November 16, 2021 14:21:33

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the Virtual Investor Roundtable Event, scheduled for Nov. 18, 2021. The CNSP overview, presented by CNS Pharmaceuticals CEO John Climaco and chief medical officer Sandra L. Silberman, MD, PhD. will begin at 9 a.m. ET. The presentation will be followed by a moderated roundtable discussion with time also included for questions and answers, which may be submitted by investors and interested parties during the live event. Questions may also be submitted for consideration before the presentation. A replay of the webcast presentation will be available following the event.

To view the full presentation, visit https://ibn.fm/79rED

To view the full press release, visit https://ibn.fm/quqyy

About CNS Pharmaceuticals Inc.

Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q3 2021 Financial, Operational Report

November 16, 2021 10:56:58

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has released is third-quarter 2021 financial report; the company also reported on operational highlights. The report noted that VVOS Q3 revenue increase more than 38% year over year, reaching $4.5 million for the third quarter of 2021 and $12.5 million for the nine months ended Sept. 30, 2021 as compared to $3.3 million and $9.8 million for the three and nine months for the same period last year. The company reported appliance sales of 2,996 total oral appliance arches, a 33% increase from the same period last year, with 8,648 total oral appliance arches, a 54% increase for the nine months ended Sept. 30, 2021, compared to the same period in 2020. Business highlights include more than 22,000 total patients have been treated with the Vivos System, compared to an estimated 13,000 for Q3 2020, with more than 1,350 dentists being trained in the use of the Vivos System and other related value-added services. In addition, the company was granted market clearance from the U.S. Food and Drug Administration for its mmRNA device designed to treat mild-to-moderate OSA, sleep-disordered breathing and snoring in adults. The company also opened an international training center in Denver and released positive results from an independent patient survey and separate clinical study related to its proprietary treatment. “The third quarter saw many positive developments for Vivos,” said Vivos chair and CEO R. Kirk Huntsman in the press release. “We recorded strong year-over-year growth, reflecting what we believe is growing recognition and adoption of our Vivos System as a treatment for mild-to-moderate sleep apnea. Our sales growth during the quarter, most notably in appliances, is beginning to reflect the impact of our previously announced strategic growth initiatives, including our expanded sales and marketing activities, featuring the broad introduction of our VivoScore diagnostic program. While we experienced a late summer decline in new VIP enrollments due in part to COVID-19, we are now generating revenue outside of our core of VIP enrollment revenue and appliance sales, including the value-added services we offer our VIPs and their patients as well as the beginnings of management revenue from our Medical Integration Division.”

To view the full press release, visit https://ibn.fm/fwFTy

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in the treatment of more than 22,000 patients worldwide by more than 1,350 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology, for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Insufficient Sleep Compromising Students’ Mental Well-Being

November 16, 2021 09:35:59

A new study has found that more than one-half of students experience poor sleep quality, with researchers noting that lack so sleep has been associated to mental health issues. The study was published in the “Annals of Human Biology” journal. It is part of the longitudinal study on the lifestyle and health of students in universities.

The study involved 1,113 women and men who attend university on a full-time basis, all aged between 16 and 25. Each participant was asked about their socioeconomic status and sleep quality, with researchers also assessing their body mass index. The researchers used this data…

NOTE TO INVESTORS: The latest news and updates relating to Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Strategic Appointment of World-Renowned Immunologist and Cytokine Expert

November 16, 2021 09:35:15

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced the appointment of Eleanor N. Fish, Ph.D., to its research and clinical advisory board. Dr. Fish is an accomplished researcher in the areas of immunology and inflammatory disorders and a member of the government of Canada’s expert scientific panel to the chief scientific advisor. She brings key expertise to FSD Pharma that will support the continued development of FSD-PEA, the company’s proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis. “I am delighted to welcome Dr. Eleanor Fish to our team,” said Dr. Lakshmi P. Kotra, B.Pharm (Hons), Ph.D., CEO of Lucid Psycheceuticals Inc., FSD Pharma’s wholly owned subsidiary. “A key aspect of Eleanor’s research is to better understand the onset and treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Her expertise and insights will be extremely valuable as we continue to advance our FSD-PEA and Lucid-MS programs, and her decades of experience in translational research will greatly benefit FSD’s current and future pipelines.”

To view the full press release, visit https://ibn.fm/q2fLJ

About FSD Pharma Inc.

FSD Pharma is a life sciences holding company with two wholly owned subsidiaries dedicated to building a portfolio of diversified therapeutic assets and innovative health care and biotech services. FSD BioSciences Inc., a wholly owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing applications of its lead compound, ultramicronized PEA, by down-regulating the cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a wholly-owned subsidiary, has exclusive worldwide rights to novel compounds shown to prevent and potentially reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, FSD is seeking to develop a unique psychoactive (psychedelic-based) therapeutic aimed at addressing neurodegenerative disorders, a multibillion-dollar mental health market. The company hopes to quickly advance its lead drug candidates through clinical trials. For more information, visit the company’s website at www.FSDPharma.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2 2022 Financial, Business Report

November 15, 2021 13:32:09

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has reported its financial and business updates for the second quarter of FY2022, the period ended Sept. 30, 2021. Notable highlights include the launch of Miboko, the company’s beta mass-market metabolic health program and the signing of a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). In addition, the company named Dr. Osama Hamdy, MD and PhD., as a new consultant on its advisory board as a consultant. Regarding the financial report, the company reported total operating expenses of an estimated $1.7 million, cash equivalents of approximately $26.8 million and the submission to its United Kingdom licensee of an initial “deposit invoice” of $513,000 as partial payment of the order received for 200,000 sensors and associated devices. “We continue to make progress in our commercializing efforts for sugarBEAT(R)in the UK and recognizing revenue from our licensee,” said Nemaura Medical CEO Dr. Faz Chowdhury in the press release. “We are also working closely with advisors to expand our footprint throughout the world to address the worldwide health crisis of diabetes using our skin-mounted needle-free CGM as an innovative solution for patients and consumers. Combined with our digital lifestyle management programs, we believe that our technology offering has the potential to be a key tool for the prevention and management of type 2 diabetes.”

To view the full press release, visit https://ibn.fm/Z5FBK

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R)and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a premarket approval application (“PMA”) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of NMRD’s BEAT diabetes program. Nemaura sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market

November 15, 2021 12:34:13

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, including cellular and protein-level details, to determine the existence of cancerous environments. At present, the company’s CDA platform “can detect up to 26 different types of cancer, which gives AnPac Bio a major advantage over industry peers in terms of cost effectiveness, multi-cancer testing, ability to detect cancer early with high sensitivity and specificity,” reads a recent article. “With its proprietary technology and being one of the first companies in the world to introduce the concept of multi-level, multi-parameter and multi-cancer (pan-cancer) screening approaches, AnPac Bio is uniquely positioned to be a leader among other prominent cancer screening and detection blood testing companies.” To view the full article, visit https://ibn.fm/Gqh17 About AnPac Bio-Medical Science Co. Ltd. AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations

November 15, 2021 12:16:08

Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredients
The company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredients
In September, Mydecine filed its final patent application for MYCO-003, one of its lead drug candidates for enhanced treatment of anxiety and post-traumatic stress disorder
MYCOF is steadily strengthening its IP portfolio as it seeks to reimagine the treatment of mental health and addiction

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), an emerging biotechnology and digital company dedicated to efficiently developing first- and second-generation novel therapeutics to treat PTSD, addiction, and other mental health disorders, has achieved a significant milestone for its drug development pipeline. The Denver-based company recently filed a technology patent application that will cover as well as allow for the creation of formulations that use nanoemulsion technology to improve, stabilize, increase bioavailability, and make repeatable properties of ingredients from… Read More>> NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Veterans Urged to Undergo Lung Cancer Screening During Lung Cancer Awareness Month

November 15, 2021 09:35:41

Cancer begins when old cells in an individual’s body begin to mutate instead of dying, growing out of control and creating abnormal cells. A team of oncologists, cardiothoracic surgeons and specialized nurse navigators from the Central Virginia Care System are urging veterans as well as individuals in high-risk groups to get screened for lung cancer this November, which is designated as Lung Cancer Awareness Month.

Lung cancer is a type of cancer that starts in the lungs and is among the leading causes of cancer deaths around the globe. The primary types of lung cancer are non-small cell lung cancer and small cell lung cancer, which have subtypes under them. The former type of lung cancer makes…

NOTE TO INVESTORS: The latest news and updates relating to AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion

November 12, 2021

November 12, 2021 15:14:41

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently signed a non-binding letter of intent (“LOI”) with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing and delivering psychedelic medicine to treat addiction. “Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for alcohol use disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM,” reads a recent article. In addition to distributing its partners’ protocols, MINDCURE will also be distributing its own protocols through iSTRYM. “With the minimum viable product (‘MVP’) version of iSTRYM already released into partner clinics across North America, the company expects to partner with 75 clinics in both Canada and the U.S. when bringing full commercial deployment in early 2022, and to double that number by Q4 2022. The distribution component opens up a new source of revenue for the company, which will help fuel further growth and expansion strategies.”

To view the full article, visit https://ibn.fm/U5mgA

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds Neuroinflammation Protein Decreases Rate of Survival in Male Patients with Glioblastoma

November 12, 2021

November 12, 2021 09:35:00

Glioblastoma is a common and aggressive type of cancer that occurs in the spinal cord or brain. This cancer is almost twice as likely to affect males and is mostly found in adults. About 12,000 individuals are diagnosed with this cancer in the United States annually. Patients diagnosed with this cancer usually experience many symptoms, including changes in personality, memory loss, persistent headaches and seizures. Now new research has found an association between glioblastoma patient survival outcomes and translocator protein 18 kDa, which is a neuro-inflammation biomarker.

This discovery could help the medical and scientific community better understand why glioblastoma is more fatal in men than in women. The research, which was reported in the September issue of the “Cancers” journal, was conducted by researchers from the National Cancer Institute, the Cleveland Clinic Lerner Research Institute and the Robert Stempel College of Public Health & Social Work, at the Florida…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement

November 11, 2021

November 11, 2021 12:48:10

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently announced a collaboration with researchers at the University of Wisconsin-Madison as part of preparations toward planned phase 2b studies. Under the partnership, Dr. Paul Hutson, PharmD, and Dr. Christopher Nicholas, Ph.D., will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for TRP-8803. The pair will also serve as investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803. “This partnership is the latest in a series of collaborations with scholars, institutions and companies,” reads a recent article. “In July, Tryp announced an agreement with the University of Michigan as part of upcoming bridging studies designed to grow its portfolio for TRP-8803 and facilitate the drug formulation’s advancement into phase 2b trials. In August, Tryp announced partnerships with Calvert Labs — an Altasciences company — and Gad Consulting Services. Under the terms of the agreement, Calvert Labs will design and execute exploratory bridging studies to generate toxicology and blood exposure level data for TRP-8803. Tryp will then work with Altasciences to perform clinical pharmacology studies in healthy volunteer patients.”

To view the full article, visit https://ibn.fm/yl1i0

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

How Virtual Monitoring Can Transform Patients’ Care

November 11, 2021

November 11, 2021 10:43:49

The advancement of innovations and technology in different sectors has made it easier to access information on almost anything you can think of. The healthcare sector in particular has experienced various changes, with medical technology reshaping healthcare, leading to the evolution of patient care and management. These advances in healthcare technology have made it possible for patients to connect with their physicians at any time, which has redefined the patient-physician connection.

The role of remote monitoring in healthcare has also been highlighted with the advancement of medical technology, especially in the early detection and treatment of cardiovascular ailments. Today, we look at how remote monitoring can make the lives of patients…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CMO to Participate in Horizons’ Veterans & Families Forum

November 10, 2021

November 10, 2021 12:49:08

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has announced that chief medical officer Dr. Rakesh Jetly will be part of the Horizons’ Veterans & Families Forum. The forum is scheduled for Nov. 10, and Jetly will be a panel member for a presentation titled “The State of Care and the Case for Psychedelic Therapy.” The panel will begin at 7:30 p.m. The event is designed specifically for veterans and will be held in NYC at the Judson Memorial Church; a virtual webcast will also be provided. The forum aims to discuss the potential of MDMA, psilocybin, ibogaine and ayahuasca treatments, specifically as they relate to helping veterans that struggle with mental health challenges following their service, along with their families. “It is an honor to participate in this Horizons event that is especially dedicated to raising awareness and advocating for our efforts to bring today’s most transformative therapies to veterans suffering from mental health issues,” said Mydecine chief medical officer Dr. Rakesh Jetly in the press release. “In ‘The State of Care and the Case for Psychedelic Therapy’ panel, I will speak about our responsibilities to veterans and families, as it truly is our duty to provide them with the most advanced and effective therapies. Today, that treatment lies within the power of psychedelics.”

To view the event, visit https://ibn.fm/NcZQT

To view the full press release, visit https://ibn.fm/gPc7k

About Mydecine Innovations Group

Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are viewed. Mydecine’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. For more information about the company, please visit www.Mydecine.com

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Results, Business Updates for Q1 2022

November 10, 2021

November 10, 2021 11:28:01

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, has reported its financial numbers and corporate update for first-quarter 2022, the period ended Sept. 30, 2021. Highlights of the report included the company’s completion of the BayMedica acquisition, positioning InMed as an industry leader in the manufacturing and commercialization of rare cannabinoids. In addition, InMed is focused on the process optimization of IntegraSyn(TM) as a solution for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP”) rare cannabinoid production. The company is also continuing the preclinical studies of its exclusive glaucoma program, INM-088, in preparation for human clinical trials. Finally, earlier this month InMed submitted an international patent application requesting commercial exclusivity for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others. On the financial side, the company closed a $12 million private placement, recorded a net loss of $3 million for the period, and reported R&D expenses of $1.5 million along with general and administrative expenses of $1.4 million. “The first quarter of fiscal 2022 saw positive momentum across all of our programs,” said InMed president and CEO Eric A. Adams in the press release. “With the completion of the BayMedica Inc. acquisition, our integrated teams are working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol(R) CBC (cannabichromene) and progressing our existing programs.”

To view the full press releases, visit https://ibn.fm/2tfvw

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing and development of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds That Insomnia Worsens Quality of Life in Adults with MDD

November 10, 2021

November 10, 2021 09:35:07

Major depressive disorder (“MDD”) is a medical condition that affects an individual’s behavior, mood and physical function, including sleep and appetite. This condition is sometimes referred to as clinical depression and is among the most common mental health conditions in the United States.

Insomnia is a sleep disorder that makes it hard for an individual to stay asleep, fall asleep or wake up too early. This disorder drains an individual’s mood and energy level, which affects different…

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market

November 9, 2021

November 9, 2021 14:13:02

Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI-based mobile application. The MiBoKo application is designed to measure and monitor the user’s metabolic health scores based on glucose tolerance and insulin resistance. The cutting-edge program provides users with personalized information by tracking their metabolism when the app and sensor are used in conjunction with one another. In addition to receiving real-time updates on their metabolic health scores, MiBoKo users will be eligible to receive weekly and monthly reports illustrating the changes in their metabolic health scores as well as providing a breakdown of how individual habits were impacting their overall health and wellbeing. A recent article quotes Nemaura CEO Dr. Faz Chowdhury as saying, “With MiBoKo, we are able to extend our proprietary non-invasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health.”

To view the full article, visit https://ibn.fm/MNSif

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a Premarket Approval Application (“PMA”) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lifestyle Changes That May Help Stop Binge Eating

November 9, 2021

November 9, 2021 09:35:47

Eating disorders such as anorexia and binge eating are serious illnesses characterized by damaging and complex relationships with body image, exercise, food and eating. Individuals suffering from binge eating disorder usually experience recurrent episodes, which involve the consumption of huge amounts of food, feeling they have lost control and experiencing feelings of shame or guilt after the binge. This disorder can cause obesity if it remains untreated, which in turn leads to other severe health issues, including gallbladder disease and type 2 diabetes.

Binge eating disorder is usually managed with medication, nutritional counseling and psychotherapy. In addition to this, lifestyle changes can also be used to manage…

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit

November 8, 2021

November 8, 2021 12:25:34

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s presentation will begin at 3:30 p.m. ET on Nov. 17. Case will provide an overview of the company, including a look at how Anpac Bio is democratizing early cancer screening and detection; he will also be available for one-on-one meetings with qualified investors. The company noted that existing early cancer screening and detection methods offer limited clinical utility and show average to nonexistent performance. The company provides its own novel and comprehensive platform featuring Cancer Differentiation Analysis (“CDA”) technology for cancer screening and detection. The technology measures biophysical properties designed to identify cancer and precancerous diseases as early as possible while also determining personalized cancer risk.

To view the presentation, visit https://ibn.fm/Dr6EM

To view the full press release, visit https://ibn.fm/O2BQf

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation, early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Climate Change Takes Heavy Toll on Mental Health

November 5, 2021

November 5, 2021 08:35:21

As the 26th Climate Change Conference (CoP26) gets underway, a number of experts are calling attention to the detrimental effects that climate change has on mental health. These experts say this component isn’t being given as much attention as it deserves by policymakers.

According to a recent report released by the World Health Organization, climate change is the most significant threat to health that humanity faces. Already, the world is witnessing loss of life due to extreme heat events, waterborne diseases, zoonotic diseases, and malnutrition…

NOTE TO INVESTORS: The latest news and updates relating to Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

November 4, 2021

November 4, 2021 12:07:54

The distribution component unlocks a new revenue source for the company, helping drive future growth
MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain
Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it
MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the proprietary technology and platform.

A recent non-binding Letter of Intent (“LOI”) was signed between Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, and Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM. This is MINDCURE’s first international partnership with industry leaders developing rigorous psychedelics protocols and drugs that can be distributed through the company’s platform to support both… Read More>> NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Panel Discussion at Wonderland: Miami

November 4, 2021

November 4, 2021 09:50:15

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will participate in Wonderland: Miami, presented by Microdose. The event is set to take place Nov. 8-9, 2021, in Miami, Florida. Tryp’s chairman and CEO Greg McKee will participate in a panel discussion entitled, “Developing Psychedelic Medicine Beyond What We Already Know,” beginning at 2:40 p.m. ET on Nov. 8. In the discussion, McKee will highlight Tryp’s leading-edge work with synthetic psilocybin for chronic pain and other indications.

To view the full press release, visit https://ibn.fm/S87TX

About Tryp Therapeutics Inc.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Patient Attitudes on Colorectal Cancer Screening Shifted During Pandemic

November 4, 2021

November 4, 2021 08:35:32

A recent survey has found that the rates of screening for colorectal cancer using colonoscopies dipped during the COVID-19 pandemic while there was an improvement in the number of people opting for at-home tests for this disease during that time.

Previous studies have aptly documented how patients were reluctant to honor their doctor appointments for illnesses that were not related to the coronavirus. However, a team of researchers from Virginia Commonwealth University (“VCU”) wanted to obtain….

NOTE TO INVESTORS: The latest news and updates relating to AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid

November 3, 2021

November 3, 2021 10:18:30

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids, today announced its filing of an international patent application demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid for the potential treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s and others. The Patent Cooperation Treaty (“PCT”) application, entitled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids,” specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons. Further, the PCT application demonstrates the subject cannabinoid compound can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function. “We are very encouraged by this initial data demonstrating potential for the use of a rare cannabinoid to improve neuronal function and provide neuroprotection for treating neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease and Huntington’s disease,” said Dr. Eric Hsu, SVP of pre-clinical research and development at InMed. “This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs. Expanding our patent portfolio to include, in addition to cannabinol (‘CBN’), an incremental rare cannabinoid for the potential treatment of major neurodegeneration indications demonstrates our continued commitment to our pharmaceutical programs and the potential of rare cannabinoids in medicine.”

To view the full press release, visit https://ibn.fm/sKPtm

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed Pharmaceuticals is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Patent Covering Formulations Featuring Nanoemulsion

November 3, 2021

November 3, 2021 09:55:34

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced that it has filed a technology patent protecting the creation of formulations that use nanoemulsion technology. The formulations aim to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. According to the announcement, the patent is intended to cover formulations that have received GRAS-certification from the U.S. Food and Drug Administration. Nanoemulsion technology is vital to Mydecine’s active drug development. “This patent filing marks a key milestone for Mydecine’s drug development pipeline in that we have introduced an additional wall of IP protection that covers important technologically innovative properties of compounds that can empower a number of over the counter supplements and consumer products,” said Mydecine CEO Josh Bartch in the press release. “The compatibility of these formulas as patent-protected ingredients has Mydecine excited to develop a wide variety of licensing opportunities. We will be able to more easily reach consumers through the expansive retail and wellness markets. As we continue to produce new methods to traditional medicinal roots, it is critical that we apply layerable patented technology to our discovery process in order to enhance the use of extracts and take advantage of increasing demand for these valuable compounds into today’s health treatments.”

To view the full press release, visit https://ibn.fm/HBsrv

About Mydecine Innovations Group

Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are viewed. Mydecine’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. For more information about the company, please visit www.Mydecine.com

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

How Medical Research Can Leverage AI Without Risking Personal Data

November 3, 2021

November 3, 2021 08:35:03

Artificial intelligence (“AI”) can be used to accelerate research and advance healthcare. It can also play a crucial role in conducting clinical trials and drug research. Using artificial intelligence to pool medical data helps save lives because AI surpasses humans in diagnosing conditions and choosing treatments. However, pooling medical data and centralizing it is unethical, given that it doesn’t align with patient privacy conditions. Centralizing data from millions of individuals also makes it vulnerable to misuse, breaches and hacks.

So, how can we yield the same benefits as pooling data without sharing patient data?

Sharing data is impossible, mainly because of privacy laws, but despite this hindrance, the need to share data continues to grow as the dependence on artificial…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Why Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Is ‘One to Watch’

November 2, 2021

November 2, 2021 13:48:22

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Founded in 2020 based on delivering to significant unmet need in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other disorders. “The company currently has four lead drug candidates, which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid PTSD, substance abuse and smoking cessation,” reads a recent article discussing the company. “Mindleap Health is a wholly owned subsidiary of Mydecine. The Mindleap platform is a virtual community that aims to foster the responsible adoption of psychedelic medicine into inner wellness. Users access the platform through the Mindleap app. Mindleap provides users with inner wellness resources to assist them in their daily mental-health journeys. The platform also seeks to support the conscious and trustworthy adoption of psychedelics into a widely accepted approach to mental health and inner wellness.”

To view the full article, visit https://ibn.fm/Guvsq

About Mydecine Innovations Group

Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are viewed. Mydecine’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. For more information about the company, please visit www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND Application to Evaluate Clinical Candidate in Phase 2a Trial in Fibromyalgia

November 2, 2021

November 2, 2021 10:05:27

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a phase 2a clinical trial. Conducted with Kevin Boehnke, Ph.D. from the University of Michigan, the trial seeks to investigate safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration with the University of Michigan and will evaluate the company’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The application includes the trial protocol and safety information details, and Tryp expects to initiate the phase 2a study in 2022 subject to a favorable review of the IND by the FDA. “Many fibromyalgia patients find insufficient relief from the currently available, FDA-approved treatments for the disease due to their limited efficacy and significant side effects,” said Dr. Boehnke. “We have an opportunity with Tryp to conduct a phase 2a study that evaluates the safety and clinical utility of psilocybin for fibromyalgia as we target the origins of the disease rather than simply treating patient symptoms.”

To view the full press release, visit https://ibn.fm/xJXsO

About Tryp Therapeutics Inc.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Research Finds That Brain Tumors Spread in a Calculated Manner

November 2, 2021

November 2, 2021 08:35:38

For the longest time, researchers thought that the process through which cancer spread to other parts of the body, in particular the brain, was random. However, a recent study conducted by researchers at the University of Southern California has found that cancer spread to other parts of the body in a somewhat organized manner.

For their study, the researchers carried out an analysis of more than 3,100 brain tumors that originated from cancers in the colon, kidney, breast, lung or skin of more than 900 patients who received treatment at the Keck Medical Center; the patients…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Study Sheds Light on Genesis of Phantom Limb Pain

November 1, 2021

November 1, 2021 10:07:58

A recent study reported in “Scientific Reports” has discovered that after an individual’s limb is amputated, areas in the brain that are responsible for sensation and movement modify their functional communication. Functional communication refers to the communication of different areas of the brain.

The study, which was conducted by researchers from the Federal University of Rio de Janeiro and the D’Or Institute for Research and Education, may assist physicians in…

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection

October 29, 2021

October 29, 2021 12:47:04

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation Analysis (“CDA”) for early detection of pre-cancerous disease and cancer. “The company has published numerous reports of clinical study results at major conferences, including ACSO conferences, and has been awarded over 100 patents globally. AnPac Bio is now able to make the claim that it is saving lives on a daily basis by detecting 26 different types of cancer very early, through the tens of thousands of commercial tests that are being performed annually,” reads a recent article. “AnPac Bio’s cancer detection CDA technology is a fully automated walk-away solution, requiring a single tube of blood that is directly loaded on to the novel and proprietary CDA device, which measures the biophysical parameters in the blood through highly sensitive bio-sensors. CDA is high-throughput and allows up to 40 samples to be loaded onto the platform deck. Each sample only requires seven minutes to measure the signals. The multi-parametric raw data is processed through a proprietary machine-learning AI-based algorithm to generate a final CDA cancer risk score. The company is vertically integrated and fully autonomous. This includes AnPac Bio’s CDA machine as well as commercial testing through laboratories in the United States and China. CDA technology can be combined with other tests, such as protein-based biomarkers, to provide more comprehensive information and data.”

To view the full article, visit https://ibn.fm/Vo4xf

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Stands Distinct in Patient Support

October 28, 2021

October 28, 2021 11:03:05

Nemaura Medical (NASDAQ: NMRD), a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, pays close attention to essential information and research that impacts the successful implementation of its solutions. Recently, the company tweeted about a study published by Dove Medical Press that included a survey of 105 participants with type 2 diabetes. The report indicated that most participants were interested in using electronic methods to communicate more with their doctors between visits. “These findings are particularly interesting to Nemaura, which has developed a proprietary technology that replaces traditional invasive methods of glucose monitoring that can be useful in disease management and diagnosis,” reads a recent article. Its BEAT(R) solution allows for continuous remote monitoring of chronic diseases and health conditions. It is designed to help people with diabetes manage their condition and potentially reverse type 2 diabetes using a combination of data from a wearable sensor and digital intervention and coaching. BEAT is combined with the company’s proprietary sugarBEAT(R) sensor platform, which is the world’s first non-invasive daily-wear continuous glucose monitoring device designed for use by people with both type 1 and type 2 diabetes as well as pre-diabetes, to trend glucose profiles. “This commitment to offering solutions designed to support patients in their treatment plans makes Nemaura distinctive.”

To view the full article, visit https://ibn.fm/fIATQ

About Nemaura Medical Inc.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mental Health America Publishes Annual Mental Health Status Report

October 28, 2021

October 28, 2021 08:35:35

Mental Health America recently published its annual report on the status of mental health within the country. The report ranks the District of Columbia and the 50 states based on various mental health prevalence and access measures.

This year’s top-three ranking states were Massachusetts, New Jersey and Pennsylvania, in that order. The bottom-three ranking states were Arizona, Idaho and Nevada, also in that order. In the past eight years, the state of Nevada has occupied…

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Successfully Synthesizes Novel Psilocin Analogue

October 27, 2021

October 27, 2021 09:28:27

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized a novel psilocin analogue, a tryptamine. This achievement means improved pharmaceutical properties to further strengthen MYCO’s library of patent-pending tryptamines. According to the announcement, the synthesis of the tryptamine results in the company adding a new compound to its growing library of compounds, supporting Mydecine’s commitment to improve the safety and efficacy of its drug-development candidates for use in therapy and medical practice. Since 2021 Mydecine has been working with Applied Pharmaceutical Innovation at the University of Alberta for its AI-driven drug-discovery program. The company noted that since the partnership began, Mydecine has increased its natural product research and novel drug design, which ultimately means the company can scale faster. “Our ability to rapidly uncover safer and more efficacious novel compounds, such as this psilocin analogue, is a true testament to the value and success of our AI-driven drug discovery program, bringing us closer to introducing the next-generation of psychedelic-based therapeutics to the market,” said Mydecine chief scientific officer Rob Roscow in the press release. “Utilizing this advanced technology, we have effectively produced an extensive base of preclinical, in vitro data that supports and expands our named drug pipeline. As we progress forward, we see great value from this development as we can now leverage the achieved receptor binding data for serotonin receptor (5-HT2A) and expand our drug pipeline focusing on the agonistic activity of psilocin and other tryptamines at different ratios on serotonin receptors.”

To view the full press release, visit https://ibn.fm/rOKdL

About Mydecine Innovations Group

Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are viewed. Mydecine’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. For more information about the company, please visit www.Mydecine.com

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Spain Opens ‘Crying Room’ in Attempt to Dispel Stigma Surrounding Mental Health

October 27, 2021

October 27, 2021 08:35:43

Data released by Spain’s government shows that more than 3,600 individuals died by suicide in the country in 2019. This makes suicide the second most common cause of death, the first being natural causes. To help ease the shame around seeking help for mental health issues, a space known as La Lloreria, or the Crying Room, uses signs that tells visitors that it’s okay to seek help when one is dealing with mental health challenges.

In addition to the signs, the room features a corner that has phones and a list of individuals, including psychologists, that visitors can call if they’re feeling down. Jon Nelsson, a Swedish student living in Madrid, stated that the building was a great way to visualize mental health issues. Nelsson added that there was a particular stigma that surrounded expressing…

NOTE TO INVESTORS: The latest news and updates relating to Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Enters Agreement with Aragen Life Sciences to Produce Innovative Drug Candidate

October 26, 2021

October 26, 2021 12:57:27

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced its entry into a development and supply agreement with Aragen Life Sciences Pvt. Ltd for the production of its innovative molecule, 5-Methoxy-2-aminoindane (“MEAI”). Aragen is a global leader in providing discovery, development and manufacturing solutions for life sciences firms under Good Manufacturing Practices. Under the agreement, Aragen will complete a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind. “Aragen is a world-class, life-sciences company with state-of-the-art manufacturing capabilities and we chose to partner with them to leverage that expertise,” said Clearmind CEO Adi Zuloff-Shani, Ph.D. in the news release. “Developing a pharmaceutical product is quite arduous; working with a manufacturer in Aragen’s caliber allows us to focus all our resources on furthering the research.” To view the full press release, visit https://ibn.fm/MPSek About Clearmind Medicine Inc. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY0. For more information about the company, visit www.ClearmindMedicine.com. About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) Target Diabetes Tech

October 26, 2021

October 26, 2021 09:50:08

The world’s largest and most powerful tech companies –Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) – are targeting an opportunity in health care that’s just too big to ignore – diabetes. Almost a third of the entire U.S. population – more than 100 million people in this country alone – are living with diabetes or are at high risk for the disease. Diabetes makes it difficult for the body to process sugar (glucose) and can lead to serious health issues and death. With $1 of every $4 of health care costs in the U.S. now spent on caring for people with diabetes, these tech giants are looking to snag a share of the multi-trillion-dollar global diabetes markets through innovation. Managing the disease relies way too much on guesswork and variables – random finger pricks to test blood sugar before trying to accurately adjust insulin dosage is far from perfect science. Plus, a multiplicity of lifestyle choices, like food and exercise, can severely impact people with… Read More>> NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Study Finds That Widespread Pain Increases Risk of Stroke, Dementia

October 26, 2021

October 26, 2021 08:35:54

A new study has found that widespread pain in the body caused by chronic pain conditions such as fibromyalgia increases an individual’s risk of dementia and stroke. For their study, the researchers analyzed health data for more than 2,000 second-generation participants in the Framingham Heart Study.

Offspring-phase participants who enrolled for the study in the 1990s underwent an extensive checkup that included a detailed pain assessment, laboratory tests and a physical exam. After this initial assessment, they underwent re-examination…

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Personalized Cancer Assessment Upon Diagnosis Could Greatly Aid Treatment Planning

October 25, 2021

October 25, 2021 08:35:19

Precision medicine involves understanding the genetic makeup of every patient’s disease and tumor before giving a diagnosis and beginning treatment while personalized medicine means recognizing that the same ailment can behave differently in different patients. A study conducted recently by researchers from the School of Medicine at UC San Diego and Moores Cancer Center at the University of California San Diego has found that carrying out genomic evaluations of advanced malignancies can help guide initial treatment.

Their findings were published…

NOTE TO INVESTORS: The latest news and updates relating to AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Identifies Market Gap, Launches ‘Desire Project’

October 22, 2021 11:37:06

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently launched its “Desire Project” to address and treat female hypoactive sexual desire disorder (“HSDD”) with MDMA-assisted psychotherapy. A first-of-its-kind study, the Desire Project, is targeting HSDD, a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. The study comprises some of the world’s leading researchers in female sexual desire and psychedelics. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from the disorder, which can damage the lives of those it affects, causing depression and anxiety — potentially destroying personal relationships. Men can also suffer from HSDD. A recent article quotes company president and CEO Kelsey Ramsden as saying, “MINDCURE has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way.”

To view the full article, visit https://ibn.fm/KkBEQ

About Mind Cure Health Inc.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Facilitating Improved Diabetes and Prediabetes Management

October 22, 2021 11:27:08

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing diagnostic devices and supporting personalized lifestyle coaching programs. Its flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor designed to help people with diabetes and prediabetes manage their glucose levels. “Over 420 million people globally are currently living with diabetes, with prediabetic cases totaling almost three times that number,” reads a recent article. “Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.”

To view the full article, visit https://ibn.fm/NfBtV

About Nemaura Medical Inc.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening

October 22, 2021 11:18:12

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is combined with protein-based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information,” explains a recent article. “Unlike most liquid-based cancer screening and detection methods, the CDA platform from AnPac Bio focuses on assessing the existing protein-based biomarkers with biophysical properties of the blood tested to signal the lead-up to serious health problems, including cancer… assessing cancer risk and its type, and predicting where the risk is highest in the future through a standard blood test. CDA is powered by a database of over 220,000 samples and cases, allowing it to serve as a new approach to disease and cancer screening.”

To view the full article, visit https://ibn.fm/exhCp

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference

October 22, 2021 08:47:55

To view the full press release, visit https://ibn.fm/nMRHT

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds Space Travel May Cause Brain Damage

October 22, 2021 08:35:45

A new study has found that spending too much time in space may cause brain damage. The study involved following a group of Russian cosmonauts who stayed on the International Space Station (“ISS”), which is orbiting 400 km from the planet’s surface. The study was conducted by researchers at the University of Gothenburg. Its findings were published in the “JAMA Neurology” scientific journal.

Previous research has found that negative changes to the human body caused by spending long periods of time in space include altered bacterial flora in the gut, deteriorating…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Showcasing Innovations in OSA Treatment at 2021 Annual Breathing Wellness Conference

October 20, 2021

October 20, 2021 14:31:34

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute. The event is taking place at Caesars Palace in Las Vegas, Nevada, from Oct. 20-23, 2021, where dentists and medical doctors from around the world will hear from the industry’s top experts on OSA about its impact on chronic conditions such as heart disease, chronic fatigue and dementia. Attendees will also have the opportunity learn how innovations in the science of dentofacial sleep medicine are forever transforming the future of dentistry. “Dentists are essential to solving the sleep and breathing epidemic as they serve as the front line to proper screening, education and, increasingly, treatment. Our annual Breathing Wellness Conference gives us a chance to educate these individuals on the dangers of OSA and share more about the latest innovations in treatment as we seek to improve the oral and overall health of patients,” said Vivos CEO Kirk Huntsman. “Rather than patch OSA with temporary, invasive solutions like CPAP machines and surgery, dentists are leading the change and focusing on potentially life-changing treatments that address the root cause of OSA.”

To view the full press release, visit https://ibn.fm/1Vep7

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Tips, Advantages of Adopting Data Analytics in Healthcare

October 20, 2021

October 20, 2021 08:35:40

Data analytics is the process of collecting, transforming and modelling data with the objective being to discover useful information that will help in decision making. Data analytics helps organizations make sense of data, which could help explain why more healthcare organizations have been adopting the use of data analytics. This process helps to not only improve their margins as well as efficiency but also drive better patient outcomes and care.

Below are a few tips and advantages that healthcare…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid to Bring Airway and Sleep, Oral Health, Orthodontic Therapy Together in Comprehensive Solution

October 19, 2021

October 19, 2021 13:22:34

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, have announced a new collaboration. Under the partnership, the companies will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. Additionally, under the agreement, Vivos and Candid will join forces to explore new research and development opportunities for device development and other alliances related to orthodontics, OSA and snoring. “Candid was built on a foundation of clinical excellence and has always put patient health first. Since launching Candid in 2017, my co-founders and I have strived to shine a light on the correlation between teeth alignment, oral health and chronic illnesses, like obstructive sleep apnea. Vivos Therapeutics and Candid are where airway and sleep, oral health and orthodontic therapy come together for the first time,” said Candid co-founder and CEO Nick Greenfield of the collaboration. “By combining Vivos’ therapeutic protocol for OSA and its VIP doctor network with Candid’s treatment methodology and CandidPro network, together we look forward to offering a full-service solution for patients suffering from OSA.”

To view the full press release, visit https://ibn.fm/5jXm8

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Israeli Researchers Find Immune Cells Aiding Tumor Development

October 19, 2021

October 19, 2021 08:35:58

Researchers from the Tel Aviv University have discovered that some immune cells in the body of a patient with cancer stop fighting cancer after a time and instead begin protecting the tumor. This breakthrough by the Israeli researchers could enhance the efficacy of treatments for cancer, in particular brain cancer.

The researchers’ findings were reported in the “Cell Reports” journal.

The researchers found that these white blood cells, known as neutrophils, are effective in killing fungi and bacteria. Normally, these cells initially…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Nemaura Medical Inc. (NASDAQ: NMRD) Announce Beta Launch of Proprietary ‘MiBoKo’ Metabolic Health Program

October 18, 2021

October 18, 2021 12:51:33

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
The company recently announced the beta launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores
US diabetes-related healthcare expenditures totalled $760 billion in 2019 alone, equating to an annual spend of over $9,000 per diabetic patient

Nemaura Medical (NASDAQ: NMRD) is a cutting-edge medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company recently carried out the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI based mobile application (https://ibn.fm/FsV8g). MiBoKo, an addition to Nemaura Medical’s diabetes-focused product portfolio, has been in development for the past 18 months and seeks to address a significant and growing mass-market opportunity which the company believes could benefit roughly a third to half of the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution

October 18, 2021

October 18, 2021 11:00:41

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. “By teaming with Candid, we are aiming to provide patients with access not only to our highly effective Vivos System, but also simultaneous access to CandidPro’s novel orthodontic treatment. We believe the Vivos-Candid collaboration will provide for the first solution that seamlessly integrates sleep and orthodontic therapy to create better patient outcomes for treating OSA and enhance overall health and wellness across the board,” said Kirk Huntsman, Vivos chairman and CEO. “We are hopeful that this joint effort will increase market penetration and accelerate revenue growth for both companies as we each attract and expand our respective North American dental and healthcare networks.”

To view the full press release, visit https://ibn.fm/vLOEy

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds That Substance-Use Disorders Heighten Risk of SARS-CoV-2 Breakthrough Infections

October 18, 2021

October 18, 2021 08:35:33

A recently conducted study has found that while the risk of SARS-CoV-2 breakthrough infection was low in vaccinated individuals with substance-use disorders, it was higher than the risk of vaccinated individuals who don’t suffer from substance use disorders. The research was conducted by researchers at the National Institute on Drug Abuse and was reported in “World Psychiatry.” Researchers from Case Western Reserve University also took part in the study.

The researchers also discovered that adverse socioeconomic determinants of health, which are common in individuals suffering from substance use disorder and health conditions that occurred simultaneously, were primarily responsible for the heightened risk of SARS-CoV-2 breakthrough…

NOTE TO INVESTORS: The latest news and updates relating to Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Focusing on What It Does Best

October 15, 2021 10:39:43

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently released its financial results for the twelve months ended May 31, reporting on its first full year of operations since incorporation in March 2020. “The company initially began the year developing a nootropic line of functional mushrooms and supplements, in line with the rising consumer use of cognitive enhancement nootropics to improve brain function. With the company’s renewed focus on its digital technology and research development activities, MINDCURE announced in August that it had discontinued the development of its nootropics line of products,” reads a recent article. According to Kelsey Ramsden, the company’s president and CEO, the strategy and infrastructure the company has put in place over the past year has positioned it well to continue the development and release of its digital therapeutics platform, iSTRYM, and to continue its research for psychedelics. Ramsden continued, “As our organization has grown and our bi-divisional technology and drug research strategy have been refined, we need to focus entirely on what we do best — creating advanced and proprietary technology for and drug research in psychedelics.”

To view the full article, visit https://ibn.fm/GTvNG

About Mind Cure Health Inc.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Enabling Hospitals with Efficient EEG Testing Solution

October 15, 2021 10:30:06

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is making it possible for all hospitals to perform EEG tests efficiently. Its neurotech ecosystem gives neurologists the resources they need to automate tedious tasks and focus their energy on the patient while simultaneously broadening their range of impact. With the unavailability of EEGs in emergency response vehicles and a majority of the hospitals in the U.S. (around 5,900 of the approximately 6,090 total hospitals lack the necessary extensive EEG tech coverage), BRSF has created a solution that includes the clinical-grade NeuroCap(TM) and the NeuroEEG(TM). “By making EEG technology more available, BRSF has created a time-saving and cost-effective solution for hospitals while simultaneously meeting the growing need for additional neurological care of the communities those hospitals serve,” reads a recent article. The company is also ready to meet the increasing needs of brain monitoring beyond emergency departments and hospitals. “Improved technology is necessary in specialized niche markets that address Alzheimer’s disease, traumatic brain injury, depression, epilepsy, ADHD, stroke, sleep disorders, dementia, migraines, and more.”

To view the full article, visit https://ibn.fm/eVOiD

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Why Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

October 15, 2021 10:09:10

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Founded in 2011, the company set out to create a single platform technology to measure blood markers at the surface of the skin. Since then, it has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and wellbeing. “Its flagship product, sugarBEAT(R), is a wearable, non-invasive, and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and pre-diabetes manage their glucose levels. Insulin users can adjunctly use sugarBEAT when calibrated with a finger-stick glucose reading,” reads a recent article. SugarBEAT offers advantages such as the fact that users no longer need to draw blood samples or prick their fingers and that a person can easily wear the disposable adhesive CGM skin patch — connected to a rechargeable transmitter with a smartphone app displaying glucose readings. Existing CGM devices must be implanted under the skin. Nemaura’s already launched products include digital solutions for weight loss and potential reversal of type 2 diabetes and glucose monitoring solutions for diabetes prevention and reversal. Other products include continuous lactate monitoring for athletic performance (non-medical) and in disease state (medical), and continuous temperature monitoring for detection of viral infection and disease propagation. To view the full article, visit https://ibn.fm/P1oj7 About Nemaura Medical Inc. Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

Study Finds That Pandemic Caused Significant Increase in Mental Health Disorders

October 15, 2021 08:39:59

Prior to the COVID-19 pandemic, anxiety disorders and major depressive disorder were already huge contributors to the worldwide burden of disease, impacting millions of individuals across the globe. Now, a recent study has found that the coronavirus pandemic has caused a significant increase in major anxiety and depressive disorders globally.

For this study, researchers identified more than 5,600 unique sources of data, almost 50 of which met the inclusion criteria. Most of the studies included were from North America and Western Europe, with a few from Central Europe, East Asia, the Asia-Pacific…

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Shining the Spotlight on Binge-Eating Disorder

October 14, 2021

October 14, 2021 13:05:53

Research shows that binge-eating disorder, which is more common than other eating disorders such as bulimia and anorexia, affects more women than men. Experts say that despite popular opinion that binge eating is a mood or phase, it is a serious issue that needs to be addressed. Regence BlueCross BlueShield’s executive medical director Dr. Amy Khan states that eating disorders often represent serious mental health conditions.

Khan explains that eating disorders are serious ailments that can impact an individual’s social, emotional and physical functioning. This is in addition to affecting their cardiovascular…

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Second-, Third-Degree Relatives of Colon Cancer Patients at Risk of Developing the Ailment

October 13, 2021

October 13, 2021 10:40:48

A new study has discovered that having relatives who have colorectal cancer heightens an individual’s risk of developing this ailment. This study, which was conducted by researchers from the University of Utah and the University of Buffalo, was published in the “Cancer Epidemiology” journal.

Physicians recommend that first-degree relatives of individuals diagnosed with early onset colorectal cancer begin screening before they reach 50 years of age. This is mainly because cases of early onset colorectal cancer have increased considerably in the last few decades. The research suggests that early screening may benefit second- and third-degree relatives as well. First-degree relatives include siblings, children and parents while second-degree…

NOTE TO INVESTORS: The latest news and updates relating to AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study

October 13, 2021

October 13, 2021 09:39:18

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company’s FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. A preformed positioner intended to prevent a child’s teeth from shifting and may seal the lips to convert mouth breathing to nose breathing, the Vivos Guide is worn according to specific protocols as children sleep for 8-10 hours each day. “Mouth breathing has long been associated with an increase in cavities. That treatment with our Guide appliances has now been shown to significantly decrease pediatric cavities is a strong indication that they also work to establish proper nasal breathing and function,” said Kirk Huntsman, Vivos chairman and CEO. “The late Dr. Christian Guilleminault of Stanford University once said, ‘The restoration of nasal breathing…may be the only valid endpoint to treating OSA.’ Clearly, any time a treatment such as our Guides can help restore and promote nasal breathing, other positive health benefits tend to happen, and these study results prove that out with respect to lowering the risk of tooth decay in children. With the global dental fillings market size valued larger than US$5 billion, we are pleased show published, peer-reviewed data demonstrating the efficacy of the Vivos Guides and significant benefits the Guides may have on pediatric dental health.”

To view the full press release, visit https://ibn.fm/qboeK

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection

October 12, 2021

October 12, 2021 12:49:25

Blood and genomic testing are becoming preferable means of early cancer screening and detection
Leaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and Guardant
AnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 different types of cancer
One of the few companies offering multi-cancer tests for risk assessment and actually contributing to the fight against cancer by having its high risk individuals (tested first by its tests and later) confirmed in the healthcare providers for cancer patients and pre-cancer patients early

Almost 1.9 million new cancer cases will be diagnosed in the United States in 2021, according to American Cancer Society (“ACS”) estimates. This number excludes basal cell, squamous cell skin cancer, and carcinoma in situ except for urinary bladder cancer. The ACS also estimates that the number of Americans to die from cancer in 2021 will be 608,570, equivalent to 1,670 people per day (https://ibn.fm/qcO5q). To address these rising cancer rates, biotechnology companies in the U.S. and worldwide are focusing on the early detection and screening of cancer through the development of proprietary technologies. AnPac Bio-Medical Science The companies currently paving the way for early cancer screening and detection include AnPac Bio-Medical Science (NASDAQ: ANPC), Illumina, Inc.’s (NASDAQ: ILMN), Grail, Inc. (now part of Illumina), Exact Sciences Co., Ltd. (NASDAQ: EXAS), and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Research Finds That Costs Incurred by Neurology Patients Have Increased Significantly

October 12, 2021

October 12, 2021 12:33:48

New research has found that the costs for office visits and diagnostic tests for neurological conditions has increased significantly in the past decade or so. The research, which was reported in the American Academy of Neurology’s online issue of “Neurology,” discovered that individuals who registered for high-deductible health plans had higher chances of incurring higher costs than individuals on other plans.

University of Michigan’s Chloe E. Hill, the author of the study, explained that this increase in costs could be harmful as it may prompt individuals to forgo diagnostic…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

October 11, 2021 13:15:06

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical property and has achieved significant results,” reads a recent article. AnPac Bio has one of the largest sample libraries in the world, with more than 220,000 samples tested. Its proprietary cancer differentiation analysis (“CDA”) technology has shown to be advantageous over traditional detection methods, allowing it to outperform in the early detection market. “As a pioneer in the application of biophysics to cancer prevention and treatment, AnPac Bio continues to report new ideas and cutting-edge technology to the public, sharing the latest clinical study and trial results, and continuing to promote collaborations between industry and academia,” said AnPac Bio CEO and Chairman Dr. Chris Yu.

To view the full article, visit https://ibn.fm/DN4Yl

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

October 11, 2021 12:30:29

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain barrier and effectively respond to pain and addiction concerns. Tryp’s efforts come as the Drug Enforcement Administration (“DEA”) recently “proposed a huge increase in the production of marijuana and psilocybin for research purposes with the hope of accelerating new federally approved therapeutic medication. The White House then issued a set of recommendations to Congress asking lawmakers to consider addressing addiction worries and proposals for new clinical research involving marijuana and psychedelics by changing the way select hallucinogen substances are regulated.”

To view the full article, visit https://ibn.fm/WOLEm

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Berubicin’s Impressive Potential in Syndicated Broadcast

October 11, 2021 08:56:34

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. According to the update, the audio press release covers CNS Pharmaceuticals’ recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. “I am extremely pleased with the progress made to-date in this potentially pivotal trial. Our team has been working intensely to open sites in the U.S. and in Europe, understanding where we can best advance this important study,” John Climaco, CEO of CNS Pharmaceuticals, said in the news release. “With hundreds of potentially competing GBM trials currently enrolling patients, the fact that we’ve been able to bring these initial sites on-line and get patients enrolled and dosed not only supports our strategic evaluation and selection, but also allows our data demonstrating Berubicin’s potential effectiveness to continue to convince the medical community that we have a new drug with impressive potential. With the de-risked profile of Berubicin, its mechanism of action, history of development, encouraging phase 1 data, and safety in study design, I am personally more optimistic about our work than at any time since joining the company.”

To view the full press release, visit https://ibn.fm/I1OVp

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Why Timely Data Analysis Is Vital in Health Care

October 11, 2021 08:35:32

We have seen a lot of businesses go digital in the last year. Researchers believe that artificial intelligence (“AI”) will be useful in various areas, including the health-care sector. Studies have shown that more than 50% of health-care facilities don’t have a strategy on how to carry out analytics and govern data. This is because the sector still lacks a structured database from which data can be read, interpreted and applied to treatments in the future. With the ongoing pandemic, new approaches to predictive analytics, data analysis and health care are needed more than ever.

Why is data analysis important for this particular sector?

Given that doctors are humans and therefore prone to human error, the probability of making a mistake will always exist. Mistakes in the field of health care not only increase…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Find Tool That Can Predict Risk of Secondary Cancer Development in Pediatric Cancer Survivors

October 8, 2021

October 8, 2021 09:20:25

A new study has discovered a tool that can identify cancer survivors who have syndromes that predispose them to cancer and heighten their risk of subsequent cancer development. The research, which was published in the “Journal of Clinical Oncology,” notes that the tool had proven to be effective in patients who hadn’t been exposed to radiation during treatment of their primary malignancies as well as in survivors of central nervous system tumors and solid tumors.

The tool integrates the specific features of tumors as well as the family and clinical history of every patient and feeds them into the tumor-particular…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Sobering Truth: Alcohol Behind More American Fatalities Compared to Drug Overdoses

October 7, 2021

October 7, 2021 08:35:23

In July, the Centers for Disease Control and Prevention released preliminary statistics which show that last year drug overdose deaths increased significantly, reaching 93,000. The opioid epidemic seems to be getting worse with each passing day, which is why it’s surprising to learn that alcohol kills more individuals in America than drug overdoses do.

The National Institute on Alcohol Abuse and Alcoholism estimates that about 95,000 individuals succumb to alcohol-related…

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Nemaura Medical Inc. (NASDAQ: NMRD) Harnesses the Power of Patient-Provider Communication

October 6, 2021

October 6, 2021 08:03:18

NMRD has developed a proprietary technology that replaces traditional invasive methods of diagnosis and healthcare observation procedures
Report notes that study participants are interested in using electronic methods to communicate more with their doctors between visits
Better communication between patients and their healthcare providers impacts adherence to prescribed treatment

According to a report published in Dove Medical Press, communication between patients and their physicians has a notable impact on adherence to prescribed treatment and improved health care (https://ibn.fm/ZMYMQ). As a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, Nemaura Medical (NASDAQ: NMRD) pays special attention to essential information and research that impacts the successful implementation of its solutions. “Many patients are not satisfied with how their doctors communicate with them,” the report states. “Patients want to be more involved in planning their care and making decisions about their treatment. It is often difficult for patients to understand all the instructions from their… Read More>> NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

RYAH Group Inc. (CSE: RYAH) Reveals Attendance at the Wall Street Reporter’s Next Super Stock Livestream Conference

October 5, 2021 12:46:06

RYAH Group is a digital healthcare analytics and technology company focused on developing tools that provide patients and doctors with the ability to accurately manage the intake in plant-based treatment
The company recently revealed its participation at the Wall Street Reporter’s ‘Next Super Stock’ livestream conference held on September 23, 2021

RYAH Group (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. The company specializes in developing volume-control IoT devices to provide accurate volume control and management for various medical purposes. RYAH Group’s management recently revealed their attendance at the Wall Street Reporter’s “Next Super Stock” livestream conference, held on… Read More>> NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming LD Micro Main Event

October 5, 2021 12:07:12

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be featured at the 14th annual LD Micro Main Event conference; the conference will be a virtual event. As part of the company’s presence at the conference, NMRD CEO Faz Chowdhury, PhD, will present an overview of the company. That presentation is scheduled for Oct. 13, 2021, at 10 a.m. ET.

To view the full presentation, visit https://ibn.fm/QtCSC

To view the full press release, visit https://ibn.fm/KjeJg

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R)and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (premarket approval application) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of NMRD’s BEAT diabetes program. Nemaura sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

What You Should Know About Traumatic Brain Injuries and PTSD

October 5, 2021 11:45:31

Brain injuries usually occur when an individual is involved in some trauma such as a fall, a blast or an accident while traumatic brain injuries occur from a sudden jolt or blow to the head. Traumatic brain injuries can be severe, moderate or mild, and are similar to concussions. Oftentimes, when individuals refer to traumatic brain injuries, they talk about the symptoms that occur following the injury, forgetting the fact that a traumatic brain injury is an actual injury.

Nearly 80% of all traumatic brain injuries in people are considered mild, with a majority of these patients fully recovering in three months without the need for special treatment. Sometimes, patients with severe or moderate…

NOTE TO INVESTORS: The latest news and updates relating to Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Featured in Latest Episode of ‘Bell2Bell’ Podcast

October 5, 2021 10:57:26

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) was featured in the “Bell2Bell Podcast,” a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Avricore Health’s CEO Hector Bremner joined the latest episode to discuss the company’s business model and its continuing efforts to lead the charge and improve early detection and screening practices throughout the health care industry. “We’re a company focused on diagnostics. We place a system within the pharmacy where a blood test or a molecular test can be done. A simple sample is collected, and the whole test takes about 15 minutes,” Bremner said. “Our technology is a cloud-based solution that networks these high-quality analyzers from companies like Abbott and is able to then create a testing network in the pharmacy… The patient gets to keep their information, of course… but really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data that can be used for study and research purposes, which is a very, very high demand out there in the sector.”

To view the full press release, visit https://ibn.fm/kD8px

About Avricore Health Inc.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find Colorectal Cancer Cases Are Higher in Minorities

October 4, 2021 13:20:51

Marvella Ford and Kristin Wallace are among researchers who have studied colorectal cancer disparities and rates. These researchers are becoming increasingly concerned as more young individuals are diagnosed with this cancer. Wallace recently published a study that looked at genetic markers which could explain the disparities in outcomes and diagnoses between whites and African Americans earlier in the year.

The study, which was…

BioMedNewsBreaks — Brain Scientific Inc. (BRSF), Piezo Motion Finalize Merger, Announce CEO

October 4, 2021 09:20:17

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has completed its merger with Piezo Motion Corp., a leading innovator of high-precision motion technology. The merger, which brings together the two teams with an objective of solving challenges using machine learning in the physical and social science markets, had been announced previously. With the merger, which involved Brain Scientific acquiring 100% of Piezo Motion’s outstanding shares, the combined company is expected to expand both its market reach and ability to bring new disruptive products to the market. According to the announcement, Hassan Kotob was named CEO and chair of the combined company. “We are very excited about this transformative transaction,” said Kotob in the press release. “The trends in teleneurology and personalized health data, which we believe Brain Scientific’s products are ideal for, continue to fuel growth in the EEG market. We further believe that the growing needs in robotic surgery and wearable drug dispensers will drive demand for Piezo Motion’s solutions. With this merger we hope to unlock many new opportunities to meet the evolving needs of patients. . . . From the capital market standpoint, we expect the merger between our companies will unlock the potential to gain access to major institutional capital and serve as an ideal platform for the company’s transition to NASDAQ or NYSE.”

To view the full press release, visit https://ibn.fm/JcZfB

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company, visit www.BrainScientific.com

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Achieves Several Key Milestones in 2021

October 4, 2021 09:06:16

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, has so far reached several key milestones in 2021. According to a recent article, these include: “raising $23 million in a bought deal short form prospectus public offering that closed in February this year. On the technology side, MCURF launched the minimum viable product (‘MVP’) of iSTRYM in Q3 2021. On the drug development and research side, the company synthesized ibogaine and has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. The company has also filed patent applications for two routes of chemical synthesis of ibogaine.” Additionally, in a recent Bell2Bell podcast episode, MCURF CEO and President Kelsey Ramsden noted that although ibogaine, a psychedelic drug, is very chemically complex and difficult to build in the lab, the MCURF team was able to synthesize it fully. For the remainder of 2021, “The company intends to spend about six months iterating the iSTRYM product in anticipation of a full commercial product launch in Q1 2022. Mind Cure Health also aims to scale up its ibogaine production to provide the psychedelic drug to researchers. Further, it is working on new research initiatives.”

To view the full article, visit https://ibn.fm/rDsl0

About Mind Cure Health Inc.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer

October 4, 2021 08:51:47

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer and disease cases. According to the announcements, those cases include 22 identified types of cancer, 25 identified types of precancer and multiple other related diseases. The company also noted that based on an initial analysis, the confirmed cases strongly correlate to CDA test scores. These results confirm that AnPac’s CDA test provides an effective method to initially screen for risks associated with cancer. “We are very pleased to reach the milestone of confirming over 2,000 cases and to achieve significant validation of CDA technology for general population cancer and pre-cancer risk assessment,” said AnPac Bio CEO and chair Dr. Chris Yu in the press release. “This is truly a breakthrough technology in catching multiple cancer and pre-cancer types earlier to prevent cancer and provide better patient outcomes. We are very proud of our contributions to the battle against cancer and we are contributing to save lives now. We are already making a significant impact in the fight against cancer through our innovative ideas (multi-cancer detection), technology development and finding potential cancer and pre-cancer earlier on a daily basis. We believe our CDA technology’s results speak for themselves and expect that public health agencies and organizations seeking the most promising tools for detecting cancer and pre-cancer earlier will look closely at AnPac Bio.”

To view the full press release, visit https://ibn.fm/df6zn

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 148 issued patents as of June 30, 2021. With one CLIA and CAP registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation, early cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

How Technological Innovation May Transform Alzheimer’s Diagnosis

October 1, 2021 14:29:51

Each year, we celebrate World Alzheimer’s Day on September 21, hoping that every passing day brings us one step closer to a cure. Alzheimer’s disease is a progressive ailment that destroys an individual’s memory and other important mental functions. Researchers believe that the disease may be caused by an abnormal buildup of proteins around and in brain cells. In its late stage, the disease causes individuals to lose their ability to carry on conversations and respond to their environments.

With new cases of the disease developing every three seconds, it becomes even more important to diagnose and…

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Devices Addressing COVID, Research-Related Challenges in Neurological Market

October 1, 2021 14:00:27

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has solved issues related to offering neurological services during COVID. The new surge in the Delta variant highlights two problems in hospitals and the neurological market: staff shortages and contamination. “When it comes to neurological services during COVID, Brain Scientific has solved these issues with its two FDA-cleared EEG technologies — the NeuroCap and NeuroEEG. Easy to administer and disposable (the NeuroCap), these low-cost devices allow staff to provide EEGs at the patient’s bedside,” reads a recent article. Brain Scientific’s NeuroCap is disposable, and both devices take five minutes to set up rather than the 30 to 45 minutes it takes to fit a traditional EEG, thus reducing contamination risk. Researchers can also administer the devices because it is not necessary to have medical training to fit the cap. “Data can be collected for more extended periods as the device is portable and worn for up to four hours. The process is also much simpler for the test subject.”

To view the full article, visit https://ibn.fm/c7FkU

About Brain Scientific Inc.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) to Host Live Event Highlighting New Potential Treatments for Alcohol Use Disorder, Binge Drinking

October 1, 2021 10:34:45

Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that it will host Psychedelics for Alcoholism. The live virtual event highlights new potential treatments for alcohol use disorder and binge drinking. Registration is open and free to all for the online event, which is slated to start at 12 p.m. ET/9 a.m. PT on Oct. 20, 2021. The event will feature brief speaker presentations followed by a discussion with a question-and-answer session. The company has curated a panel of scientists, thought leaders, therapists and pundits to share insight on the mounting evidence suggesting the effectiveness of psychedelics, and specifically MEAI, in the regulation of excessive drinking. Clearmind representatives will also provide an update on the company’s MEAI-based medicines and their potential for the treatment of alcohol use disorder and binge drinking. “We ’re in the middle of a psychedelic renaissance that is revolutionizing the way we treat mental disorders,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind. “We put this event together to increase awareness of the advances being made in the field, and more specifically generate awareness of the work Clearmind is doing with regard to alcohol use and binge drinking.”

To view the full press release, visit https://ibn.fm/4jFaW

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY0. For more information about the company, visit www.ClearmindMedicine.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%